Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;95(35):e4592.
doi: 10.1097/MD.0000000000004592.

Selenium-binding protein 1 in head and neck cancer is low-expression and associates with the prognosis of nasopharyngeal carcinoma

Fasheng Chen  1 , Chen Chen, Yangang Qu, Hua Xiang, Qingxiu Ai, Fei Yang, Xueping Tan, Yi Zhou, Guang Jiang, Zixiong Zhang
Affiliations

Selenium-binding protein 1 in head and neck cancer is low-expression and associates with the prognosis of nasopharyngeal carcinoma

Fasheng Chen et al. Medicine (Baltimore). 2016 Aug.

Abstract

Background: Selenium-binding protein 1 (SELENBP1) expression is reduced markedly in many types of cancers and low SELENBP1 expression levels are associated with poor patient prognosis.

Methods: SELENBP1 gene expression in head and neck squamous cell carcinoma (HNSCC) was analyzed with GEO dataset and characteristics of SELENBP1 expression in paraffin embedded tissue were summarized. Expression of SELENBP1 in nasopharyngeal carcinoma (NPC), laryngeal cancer, oral cancer, tonsil cancer, hypopharyngeal cancer and normal tissues were detected using immunohistochemistry, at last, 99 NPC patients were followed up more than 5 years and were analyzed the prognostic significance of SELENBP1.

Results: Analysis of GEO dataset concluded that SELENBP1 gene expression in HNSCC was lower than that in normal tissue (P < 0.01), but there was no significant difference of SELENBP1 gene expression in different T-stage and N-stage (P > 0.05). Analysis of pathological section concluded that SELENBP1 in the majority of HNSCC is low expression and in cancer nests is lower expression than surrounding normal tissue, even associated with the malignant degree of tumor. Further study indicated the low SELENBP1 expression group of patients with NPC accompanied by poor overall survival and has significantly different comparing with the high expression group.

Conclusion: SELENBP1 expression was down-regulated in HNSCC, but has no associated with T-stage and N-stage of tumor. Low expression of SELENBP1 in patients with NPC has poor over survival, so SELENBP1 could be a novel biomarker for predicting prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Analysis of SELENBP1 gene expression in cancer and normal tissue from Gene Expression Omnibus (GEO) dataset. (A) Expression of SELENBP1 gene is relatively low in total cancer in comparison with normal tissue. (B) Expression of SELENBP1 gene is relatively low in head and neck squamous cell carcinoma (HNSCC) compared with normal tissue. (C) Expression of SELENBP1 gene in beginning and advanced tumor stage is lower than margin of tumor. (D) Expression of SELENBP1 gene in different T-stage of HNSCC has no statistically significance. (E) Expression of SELENBP1 gene in different N-stage of HNSCC has no statistically significance. (F) Expressing of SELENBP1 gene in different grade of HNSCC has no statistically significance.
Figure 2
Figure 2
The different expressions of SELENBP1 in head and neck squamous cell carcinoma (HNSCC) detected by IHC. All magnifications 400×. (A) Representative images of immunohistochemistry (IHC) staining for SELENBP1 expression is very low (−) in HNSCC. (B) Representative images of IHC staining for SELENBP1 expression is low (±) in HNSCC. (C) Representative images of IHC staining for SELENBP1 expression is high (+) in HNSCC. (D) Representative images of IHC staining for SELENBP1 expression is very high (++) in HNSCC.
Figure 3
Figure 3
The expressions of SELENBP1 compared to surrounding tissue in HNSCC detected by (IHC). All magnification 400×. Black arrow represents nasopharyngeal carcinoma cells. Red arrow represents normal mucosa cells. Green arrow represents normal lymphocytes. (A,C) Representative images of IHC staining for SELENBP1 in cancer nest comparing to normal mucosa. (B,D) Representative images of IHC staining for SELENBP1 in cancer nest comparing to peripheral tissue.
Figure 4
Figure 4
The result of SELENBP1 expressions in HNSCC and normal tissues. (A and B) Results of SELENBP1 expressions in total head and neck squamous cell carcinoma (HNSCC) and normal tissues. (C and D) Results of SELENBP1 expressions in respective HNSCC and normal tissues.
Figure 5
Figure 5
Expression of SELENBP1 in nasopharyngeal carcinoma (NPC) is associated with the prognosis of patients. (A) The low expressions of SELENBP1 is associated with overall survival of patients with NPC. (B) The low expressions of SELENBP1 is associated with tumor recurrence-free survival of patients with NPC. (C) The low expressions of SELENBP1 is associated with tumor metastasis–free survival of patients with NPC.
Figure 6
Figure 6
The correlation of the SELENBP1 expression and tumor N-stage, T-stage, and tumor grade.
See this image and copyright information in PMC

References

    1. Klein EA. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004; 1031:234–241. - PubMed
    1. Davis C, Tsuji PA, Milner JA. Selenoproteins and cancer prevention. Ann Rev Nutr 2012; 32:73–95. - PubMed
    1. Rayman MP. Selenium and human health. Lancet 2012; 379:1256–1268. - PubMed
    1. Chen YC, Sandeep PK, Andrea M, et al. Is selenium a potential treatment for cancer metastasis? Nutrients 2013; 5:1149–1168. - PMC - PubMed
    1. Jeong JY, Wang Y, Sytkowski AJ. Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun 2009; 379:583–588. - PubMed

MeSH terms

Substances